Inmed Pharmaceuticals INC. (INM) — 8-K Filings

All 8-K filings from Inmed Pharmaceuticals INC.. Browse 41 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (41)

InMed Pharmaceuticals Files 8-K — Dec 18, 2025 Risk: low
InMed Pharmaceuticals Inc. filed an 8-K on December 18, 2025, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and finan
InMed Pharmaceuticals Files 8-K — Dec 15, 2025 Risk: low
InMed Pharmaceuticals Inc. filed an 8-K on December 15, 2025, reporting on events that occurred on December 12, 2025. The filing pertains to 'Other Events' and
InMed Pharmaceuticals Files 8-K — Nov 19, 2025 Risk: low
InMed Pharmaceuticals Inc. filed an 8-K on November 19, 2025, reporting an event on November 18, 2025. The filing indicates a Regulation FD Disclosure and inclu
InMed Pharmaceuticals Files 8-K: Officer/Director Changes & Financials — Oct 16, 2025 Risk: medium
InMed Pharmaceuticals Inc. filed an 8-K on October 16, 2025, reporting events as of October 14, 2025. The filing indicates changes related to the departure of d
InMed Pharmaceuticals Announces Board Changes and Compensation Updates — Oct 14, 2025 Risk: medium
InMed Pharmaceuticals Inc. announced on October 9, 2025, a series of significant corporate actions including the departure of two directors, the election of two
InMed Pharmaceuticals Files 8-K — Sep 8, 2025 Risk: low
InMed Pharmaceuticals Inc. filed an 8-K on September 8, 2025, reporting an event on September 5, 2025. The filing is a current report and includes financial sta
InMed Pharmaceuticals Inc. Files Current Report — Jul 28, 2025 Risk: low
InMed Pharmaceuticals Inc. filed an 8-K on July 28, 2025, reporting a current event. The filing details the company's principal executive offices located at Sui
InMed Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — Jun 30, 2025 Risk: medium
InMed Pharmaceuticals Inc. announced on June 24, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of
InMed Pharmaceuticals Files 8-K with Corporate Updates — Jun 24, 2025 Risk: low
InMed Pharmaceuticals Inc. filed an 8-K on June 24, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the com
InMed Pharmaceuticals Files 8-K with Key Corporate Updates — Jun 13, 2025 Risk: medium
InMed Pharmaceuticals Inc. filed an 8-K on June 13, 2025, reporting on several key events as of June 12, 2025. These include entering into a material definitive
InMed Pharmaceuticals Files 8-K Current Report — May 13, 2025 Risk: low
InMed Pharmaceuticals Inc. filed an 8-K on May 13, 2025, reporting an event on May 12, 2025. The filing indicates it is a current report pursuant to Section 13
InMed Pharmaceuticals Files 8-K — Apr 25, 2025 Risk: low
InMed Pharmaceuticals Inc. filed an 8-K on April 25, 2025, reporting on other events and financial statements. The filing does not contain specific financial fi
InMed Pharmaceuticals Files 8-K — Apr 8, 2025 Risk: low
InMed Pharmaceuticals Inc. filed an 8-K on April 8, 2025, reporting an event that occurred on April 4, 2025. The filing indicates 'Other Events' and 'Financial
InMed Pharmaceuticals Inc. Reports Board and Executive Changes — Feb 14, 2025 Risk: medium
InMed Pharmaceuticals Inc. announced on February 10, 2025, a change in its board of directors and executive compensation arrangements. The filing details the de
InMed Pharmaceuticals Files 8-K — Feb 13, 2025 Risk: low
InMed Pharmaceuticals Inc. filed an 8-K on February 13, 2025, reporting an event on February 12, 2025. The filing is categorized under Regulation FD Disclosure
InMed Pharmaceuticals Files 8-K — Feb 3, 2025 Risk: low
InMed Pharmaceuticals Inc. filed an 8-K on February 3, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not con
InMed Pharmaceuticals Inc. Files Current Report — Jan 22, 2025 Risk: low
InMed Pharmaceuticals Inc. filed an 8-K on January 22, 2025, reporting a current event. The filing indicates the company's principal executive offices are locat
InMed Pharmaceuticals Files 8-K — Jan 21, 2025 Risk: low
InMed Pharmaceuticals Inc. filed an 8-K on January 21, 2025, reporting a current event. The filing does not contain specific financial details or significant bu
Ares Management to Acquire InMed Pharmaceuticals for $100M — Dec 19, 2024 Risk: medium
InMed Pharmaceuticals Inc. announced on December 18, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Ares Management LLC
InMed Pharmaceuticals Inc. Files 8-K: Material Agreement & Equity Sales — Dec 18, 2024 Risk: medium
InMed Pharmaceuticals Inc. announced on December 13, 2024, that it entered into a material definitive agreement. The company also disclosed unregistered sales o
InMed Pharmaceuticals Files 8-K — Nov 20, 2024 Risk: low
InMed Pharmaceuticals Inc. filed an 8-K on November 20, 2024, reporting an event on November 19, 2024. The filing pertains to Regulation FD Disclosure and Finan
InMed Pharmaceuticals Files 8-K — Nov 15, 2024 Risk: low
InMed Pharmaceuticals Inc. filed an 8-K on November 14, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the
InMed Pharmaceuticals Files 8-K: Rights, Reg FD, and More — Nov 12, 2024 Risk: low
On November 8, 2024, InMed Pharmaceuticals Inc. filed an 8-K report detailing material modifications to the rights of security holders, a Regulation FD disclosu
InMed Pharmaceuticals Faces Delisting Notice — Nov 5, 2024 Risk: high
InMed Pharmaceuticals Inc. filed an 8-K on November 1, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is base
InMed Pharmaceuticals Files 8-K — Oct 24, 2024 Risk: low
InMed Pharmaceuticals Inc. filed an 8-K on October 24, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the
InMed Pharmaceuticals to be Acquired by Capstone Development — Oct 23, 2024 Risk: medium
InMed Pharmaceuticals Inc. announced on October 22, 2024, that it has entered into a definitive agreement to be acquired by Capstone Development, LLC. The trans
InMed Pharmaceuticals Files 8-K — Sep 26, 2024 Risk: low
InMed Pharmaceuticals Inc. filed an 8-K on September 26, 2024, to report other events and financial statements. The filing does not contain specific details abo
InMed Pharmaceuticals Faces Delisting Concerns — Sep 20, 2024 Risk: high
InMed Pharmaceuticals Inc. filed an 8-K on September 20, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The f
InMed Pharmaceuticals Files 8-K — Aug 21, 2024 Risk: low
InMed Pharmaceuticals Inc. filed an 8-K on August 21, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not cont
InMed Pharmaceuticals to Acquire BayMedica for $10M — Aug 20, 2024 Risk: medium
InMed Pharmaceuticals Inc. announced on August 20, 2024, that it has entered into a definitive agreement to acquire BayMedica Inc. for an aggregate purchase pri
InMed Pharmaceuticals Files 8-K — Jul 30, 2024 Risk: low
InMed Pharmaceuticals Inc. filed an 8-K on July 30, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the com
InMed Pharmaceuticals Inc. Files 8-K for Material Agreement — Jun 28, 2024 Risk: medium
On June 27, 2024, InMed Pharmaceuticals Inc. entered into a material definitive agreement. The company, incorporated in British Columbia with its principal exec
InMed Pharmaceuticals Acquires BayMedica for $10M — Jun 11, 2024 Risk: medium
InMed Pharmaceuticals Inc. announced on June 10, 2024, that it has entered into a definitive agreement to acquire BayMedica Inc. for approximately $10 million i
InMed Pharmaceuticals Files 8-K — Apr 18, 2024 Risk: low
InMed Pharmaceuticals Inc. filed an 8-K on April 18, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not co
InMed Pharmaceuticals Acquires Canna-Core for $1.5M — Apr 16, 2024 Risk: medium
InMed Pharmaceuticals Inc. announced on April 16, 2024, that it has entered into a definitive agreement to acquire Canna-Core Inc. for an aggregate purchase pri
InMed Pharmaceuticals Files 8-K — Apr 5, 2024 Risk: low
InMed Pharmaceuticals Inc. filed an 8-K on April 4, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, incorporated
InMed Pharmaceuticals Faces Delisting Concerns — Mar 20, 2024 Risk: high
InMed Pharmaceuticals Inc. filed an 8-K on March 19, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is also d
InMed Pharmaceuticals Files 8-K for Feb 13 Event — Feb 14, 2024 Risk: low
InMed Pharmaceuticals Inc. filed an 8-K on February 14, 2024, reporting an event that occurred on February 13, 2024. The filing indicates disclosure under Regul
InMed Pharma Reports Leadership Changes & Comp Arrangements — Feb 9, 2024 Risk: medium
InMed Pharmaceuticals Inc. filed an 8-K on February 8, 2024, to report the departure of directors or certain officers, election of directors, and appointment of
InMed Pharma Confirms Nasdaq Listing for Common Shares — Jan 19, 2024
InMed Pharmaceuticals Inc. filed an 8-K on January 19, 2024, reporting an event that occurred on January 18, 2024. This filing is a routine disclosure indicatin
InMed Pharma Files Routine 8-K, Confirms Address & Contact Info — Jan 16, 2024
This 8-K filing from InMed Pharmaceuticals Inc. on January 16, 2024, is a routine administrative update, primarily confirming its current address as Suite 310 -

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX